Table 2 Randomized trials comparing ABVD... | American Society of Hematology

Table 2

Randomized trials comparing ABVD or regimen of equivalent efficacy alone with treatment that includes RT

	Accrual years	Protocol	N	Median follow-up, mo	Treatment	OS, %	OS, yr	P	FFDP/FFTF/EFS, %	FFDP/FFTF/EFS, yr	P
Tata²⁶	1993-1996		99*	63	ABVD × 6	98	8	.26	94	8	.29
					ABVD × 6 + IFRT‡	100	8		97	8
CCG²⁸	1995-1998	5942	215†	NR	COPP-ABV × 4	100	3	NR	91	3	NR
					COPP-ABV × 4 + IFRT‡	100	3		97	3
MSKCC²⁷	1990-2000		152	67	ABVD × 6	90	5	.08	81	5	.61
					ABVD × 6 + RT‡	97	5		86	5
NCIC CTG-ECOG²	1994-2002	HD.6	399	136	ABVD × 4-6	94	12	.04	87	12	.05
					EFRT (favorable cohort); ABVD × 2 + EFRT (unfavorable cohort)‡	87	12		92	12

	Accrual years	Protocol	N	Median follow-up, mo	Treatment	OS, %	OS, yr	P	FFDP/FFTF/EFS, %	FFDP/FFTF/EFS, yr	P
Tata²⁶	1993-1996		99*	63	ABVD × 6	98	8	.26	94	8	.29
					ABVD × 6 + IFRT‡	100	8		97	8
CCG²⁸	1995-1998	5942	215†	NR	COPP-ABV × 4	100	3	NR	91	3	NR
					COPP-ABV × 4 + IFRT‡	100	3		97	3
MSKCC²⁷	1990-2000		152	67	ABVD × 6	90	5	.08	81	5	.61
					ABVD × 6 + RT‡	97	5		86	5
NCIC CTG-ECOG²	1994-2002	HD.6	399	136	ABVD × 4-6	94	12	.04	87	12	.05
					EFRT (favorable cohort); ABVD × 2 + EFRT (unfavorable cohort)‡	87	12		92	12

FFDP indicates freedom from disease progression; Tata, Tata Memorial Hospital, Mumbai; CCG, Children's Cancer Group; MSKCC, Memorial-Sloan Kettering Cancer Center; and NR, not reported.

Includes stage I or II patients only.

†

Includes group 1 patients only;

‡

Control therapy.

View Large

This Feature Is Available To Subscribers Only